Why was Belviq removed the marketplace?

People began filing Belviq lawsuits shortly following the U.S. Food and Drug Administration asked the drug's manufacturer, Eisai Inc., to pull it off the market. A five-year study of Belviq users convinced the FDA that the drug posed an increased cancer risk.
Belviq, or lorcaserin, was a weight loss drug approved by the FDA in 2012 to treat obesity. It was also prescribed to overweight people who'd serious weight-related health conditions such as for instance diabetes and high blood pressure.

It absolutely was available by prescription in its original form and in a protracted release version, Belviq XR. Both are the subject of Belviq lawsuits.
Arena Pharmaceuticals manufactures Belviq at its facility in Switzerland. Eisai Inc. marketed and distributed Belviq in the United States. Both companies are named in lawsuits.

Cancer Link Led Individuals to File Belviq Lawsuits

On Feb. 13, 2020, the FDA requested that Eisai Inc. voluntarily withdraw the drug within the potential cancer link. The agency based its decision on results from a five-year study of Belviq users that the company had conducted to ensure there were no serious cardiovascular risks related to the drug.

“We are taking this action because we think that the risks of lorcaserin outweigh its benefits centered on our completed overview of results from the randomized clinical trial assessing safety,” the FDA announcement read.

Once the FDA approved Belviq, it required Eisai to conduct a long-term study to the drug's cardiovascular effects. The analysis involved 12,000 people, some taking Belviq and others having a placebo.

Data from the trial showed that 7.7 percent of the folks taking Belviq developed cancer, in comparison to 7.1 percent taking the placebo.

Belviq users who developed any one of three various kinds of cancer began filing lawsuits shortly following the FDA announcement.

The organization complied with the FDA's request, but it issued a record saying that its interpretation of data from the research differed from the FDA's.

“The business's assessment is that Belviq and Belviq XR continue to have a positive benefit-risk profile in the in-patient population for which they are indicated,” the statement read.

The statement added that Eisai respected the FDA's decision and was dealing with the agency to get rid of its drug from the market.

For more details please visit Risks of taking Belviq.